

# 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study

Bin Cao, MD

National Center for Respiratory Medicine
Institute of Respiratory Medicine, Chinese Academy of Medical Science
National Clinical Research Center for Respiratory Diseases


China-Japan Friendship Hospital

caobin\_ben@163.com

#### SARS-CoV-2 Viral sepsis—Observations and Hypotheses

#### **Multi-organ dysfunction**


- Pneumonia, Respiratory failure,
   Acute respiratory distress syndrome
- Metabolic acidosis and internal environment disorders
- Acute kidney injury
- Acute cardiac injury
- ......



——Viral Sepsis

Ren L et al. Chin Med J 2020; 133(9):1015-1024 Huang C et al. Lancet 2020; 395(10223): 497-506 Li H et al. Lancet. 2020;395(10235):1517-1520

#### Multiple organ dysfunction and complications in hospitalized patients



Complications	Prevalence
Pneumonia	75%
Acute respiratory distress syndrome	15%
Acute liver injury	19%
Cardiac injury	7%-17%
Thromboembolic events	10%-25%
Acute kidney injury	9%
Neurologic manifestations	8%
Acute cerebrovascular disease	3%
Shock	6%

## **Clinical questions**

- Will the multiple organ dysfunctions persist or new onset damage post-acute occur?
- What are the clinical picture of the aftermath of COVID-19?

#### THE LANCET



#### Objectives

- Describe the health consequences of patients with COVID-19 who have been discharged from hospital at 6 months after symptom onset.
- Identify the potential risk factors associated with the consequences, in particular disease severity.

#### **Inclusion & Exclusion criteria**

- Inclusion criteria
  - All laboratory confirmed COVID-19 patients who were discharged from Jin Yin-tan Hospital (Wuhan city, China) from January 7, 2020 to May 29, 2020
- Exclusion criteria
  - Dead before this follow-up visit
  - For whom follow-up would be difficult because of psychotic disorder, dementia, or readmission to hospitals
  - Unable to move freely due to concomitant osteoarthropathy disease or immobile before or after discharge due to diseases such as stroke or pulmonary embolism
  - Declined to participate
  - Unable to be contacted
  - Living outside of Wuhan or in nursing or welfare homes


#### Schedule

- The appointment for the follow-up visit was set by trained medical staff via telephone
- Follow-up was conducted in the outpatient clinic of Jin Yin-tan Hospital
- Examination items
  - ✓ Physical examination
  - ✓ Self-reported symptom questionnaire
  - ✓ mMRC dyspnea scale
  - ✓ EQ-5D-5L questionnaire & EQ-VAS
  - √ 6-min walking test

- ✓ Blood test (include antibody test\*)
- ✓ Chest HRCT #
- ✓ Pulmonary function test\*
- ✓ Ultrasonography of lower limbs vein and abdomen#

<sup>\*:</sup> Participants who had been previously enrolled in the Lopinavir Trial for suppression of SARS-CoV-2 in China<sup>[1]</sup>. #: A stratified disproportional random sampling procedure according to severity scale was used to select patients to undergo special tests.

## Flow chart of COVID-19 patients discharged from Jin Yin-tan hospital during January 7, 2020 and May 29, 2020



■ 1733 enrolled

scale 3: 439

scale 4: 1172

scale 5-6: 122

Median age: 57 years


Median follow-up time

after symptom onset: 186 days

after hospital discharge: 153 days


mortality after discharge: 1.3% (33/2469)

## Persisting symptoms at follow-up




- More than 70% of patients reported at least one symptom.
- The most common symptoms are fatigue/muscle weakness(63%) and sleep difficulty(26%).

## **EQ-5D-5L** questionnaire



- More severe patients endorsed more problems
- More than 20% reported psychological complications
- More than 90% had no problems in mobility, usual activity and personal care at follow-up.

## Impaired lung function and exercise capacity




ns: no significant, \*: p<0.05,LLN: lower limit of normal range.


## Lung CT image at follow-up

Characteristics	Scale 3	Scale 4	Scale 5-6
Number of patients	95	163	95
At least one abnormal CT pattern	49 (52%)	87/161 (54%)	50/92 (54%)
GGO	39 (41%)	78/161 (48%)	41/92 (45%)
Irregular lines	10 (11%)	24/161 (15%)	22/92 (24%)
Consolidation	0	4/161 (2%)	0
Interlobular septal thickening	1 (1%)	2/161 (1%)	0
Subpleural line	6 (6%)	5/161 (3%)	4/92 (4%)
Reticular pattern	0	1/161 (1%)	1/92 (1%)
Volume of lung lesions, cm <sup>3</sup>	1.6 (0.6-5.6)	3.3 (0.8-12.4)	29.1 (4.6-77.3)
Volume of consolidation, cm <sup>3</sup>	0.2 (0.1-0.4)	0.3 (0.1-1.0)	1.6 (0.2-4.4)
Volume of GGO, cm <sup>3</sup>	1.4 (0.6-4.7)	2.9 (0.7-10.0)	26.3 (4.3-73.3)
Volume ratio of lung lesion to total lung, %	0.0 (0.0-0.1)	0.1 (0.0-0.3)	0.7 (0.1-2.2)
Volume ratio of consolidation to total lung, %	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.0 (0.0-0.1)
Volume ratio of GGO to total lung, %	0.0 (0.0-0.1)	0.1 (0.0-0.2)	0.6 (0.1-1.9)
CT score	3.0 (2.0-5.0)	4.0 (3.0-5.0)	5.0 (4.0-6.0)


At six-month after symptom onset, around half patients still have at least one abnormal CT pattern, GGO is the most common pattern.


## Risk factors of diffusion impairment and CT score






#### Risk factors of anxiety/depression and fatigue/muscle weakness





#### Temporal changes of seropositivity and antibody titers against SARS-CoV-2



- The seropositivity and titer of neutralizing antibody are significantly lower compared with that at acute phase.
- The decline of neutralising antibodies raises concern for SARS-CoV-2 re-infection.

#### **Extrapulmonary organ manifestations**

- For patients with lymphocyte count less than  $0.8 \times 10^9 / L$  at acute phase, 97% had lymphocyte counts  $0.8 \times 10^9 / L$  or more at follow-up.
- No deep venous thrombosis was observed in 390 patients who underwent ultrasonography at follow-up.
- 58 patients were newly diagnosed with diabetes at follow-up.
- 13% (107 of 822) of the patients who did not develop AKI during their hospital stay and presented with normal renal function, exhibited a decline in eGFR (<90 mL/min\*1·73 m²) at follow-up.

#### **Summary**

- At 6 months after illness onset, most patients had at least one symptom, with fatigue or muscle weakness being the most frequently reported symptom
- More severe patients during hospitalization had more severe lung diffusion capacity deterioration and chest imaging anomaly
- Critically ill patients deserve more attention during hospitalization and after discharge
- Longer and larger follow-up study are necessary to understand the full spectrum of health consequences of COVID-19, ranging from non-hospitalized patients, hospitalized patients to ICU survivors.
- Multidisciplinary, multicentre, and multinational collaborations are needed to face up the long COVID.

Huang et al. Lancet. 2021.

Cortinovis M. The Lancet, 2021.

## **Acknowledgements**

#### **China-Japan Friendship Hospital**

Chen Wang; Yeming Wang; Lixue Huang; Xiaoying Gu; Min Liu; Guohui Fan; Yong Li; Jiuyang Xu

#### **Wuhan Jin-yintan Hospital**

Dingyu Zhang; Chaolin Huang; Xia Li; Liang Kang; Li Guo; Xing Zhou; Jianfeng Luo; Zhenghui Huang; Shengjin Tu; Yue Zhao; Li Chen; Decui Xu; Yanping Li; Caihong Li; Lu Peng

#### **CAMS&PUMC**

Chen Wang; Jianwei Wang; Lili Ren; Li Guo; Geng Wang; Ying Wang; Jingchuan Zhong


#### **Cooperators:**

Wuhan Jin-yintan Hospital

Key Laboratory of Respiratory Disease Pathogenomics, Chinese Academy of Medical Sciences and Peking Union Medical College

All patients who participated in this study and their families
All health-care workers involved in the diagnosis and treatment of patients
All staff of this follow-up study team














## The ongoing COVID-19 Pandemic



As of 2021/2/2, there has been more than 102 million cases with more than 2.2 million death

## Key pathophysiological mechanisms of COVID-19



- Direct virus-mediated cell damage;
- Dysregulation of the RAAS as a consequence of downregulation of ACE2 related to viral entry;
- Endothelial cell damage and thrombo-inflammation
- Dysregulation of the immune response and hyperinflammation caused by inhibition of interferon signaling by the virus, T cell lymphodepletion, and the production of proinflammatory cytokines, particularly IL-6 and TNF $\alpha$